- Trials with a EudraCT protocol (6)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (169)
6 result(s) found for: BOD.
Displaying page 1 of 1.
EudraCT Number: 2020-004066-19 | Sponsor Protocol Number: CV-NCOV-005 | Start Date*: 2020-12-18 | |||||||||||
Sponsor Name:CureVac AG | |||||||||||||
Full Title: COVID-19: A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Clinical Study Evaluating the Safety and Immunogenicity of Investigational SARS-CoV-2 mRNA Vaccine CVnCoV in Adult Health Care ... | |||||||||||||
Medical condition: Vaccination for prophylaxis of COVID-19 (healthy adults) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-006677-26 | Sponsor Protocol Number: 68797373 | Start Date*: 2022-06-22 | ||||||||||||||||
Sponsor Name:Maastricht University | ||||||||||||||||||
Full Title: Metabolic effects of ketohexokinase inhibition in individuals with non-alcoholic fatty liver disease | ||||||||||||||||||
Medical condition: Healthy volunteers (non-alcoholic fatty liver disease) | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: NL (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2007-000381-20 | Sponsor Protocol Number: 27820 | Start Date*: 2007-11-16 | |||||||||||
Sponsor Name:Merck Serono S.A. - Geneva | |||||||||||||
Full Title: A Phase IIIb, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Extension Trial to Evaluate the Safety and Tolerability of Oral Cladribine in Subjects with Relapsing-Remitting Multiple... | |||||||||||||
Medical condition: Relapsing Remitting Multiple Sclerosis (RRMS) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: FI (Completed) FR (Completed) GB (Completed) CZ (Completed) BE (Completed) EE (Completed) AT (Completed) PT (Completed) NL (Completed) DE (Completed) DK (Completed) IT (Completed) GR (Completed) LV (Completed) LT (Completed) BG (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002204-33 | Sponsor Protocol Number: C32322 | Start Date*: 2007-03-02 | |||||||||||
Sponsor Name:UCB Pharma S.A. | |||||||||||||
Full Title: Double-blind, placebo-controlled, randomized, parallel-group Phase II study in subjects with relapsing forms of multiple sclerosis (MS) to evaluate the safety, tolerability, and effects of two dose... | |||||||||||||
Medical condition: Relapsing forms of multiple slerosis | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) FI (Prematurely Ended) HU (Completed) SE (Prematurely Ended) GB (Completed) ES (Completed) FR (Completed) NL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2020-004272-17 | Sponsor Protocol Number: CLO-SCB-2019-003 | Start Date*: 2021-03-25 | |||||||||||
Sponsor Name:Clover Biopharmaceuticals AUS Pty Ltd | |||||||||||||
Full Title: A Double-blind, Randomized, Controlled, Phase 2/3 Study to Evaluate the Efficacy, Immunogenicity, and Safety of CpG 1018/Alum-Adjuvanted Recombinant SARS-CoV-2 Trimeric S-protein Subunit Vaccine (S... | |||||||||||||
Medical condition: SARS-CoV-2-mediated COVID-19 | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: BE (Completed) DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-001449-33 | Sponsor Protocol Number: PO4849 | Start Date*: 2007-07-18 | |||||||||||
Sponsor Name:Schering Plough Research Institute (SPRI), A Division of Schering Corporation | |||||||||||||
Full Title: A study of the efficacy, safety, and quality of life (QOL) in patients with chronic idiopathic urticaria dosed with AERIUS Tablets (5 mg, 10 mg, or 20 mg once daily). | |||||||||||||
Medical condition: Subjects with an active episode of chronic idiopathic urticaria (CIU) and are taking a second-generation antihistamine will be selected for the study. The urticaria activity score (UAS) must be be... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) CZ (Completed) SK (Completed) SE (Completed) GR (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
